Innovent Biologics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IVBXF research report →
Companywww.innoventbio.com
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases.
- CEO
- De-Chao Yu
- IPO
- 2019
- Employees
- 5,659
- HQ
- Suzhou, CN
Price Chart
Valuation
- Market Cap
- $17.87B
- P/E
- 149.76
- P/S
- 9.46
- P/B
- 6.29
- EV/EBITDA
- 92.84
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 76.42%
- Op Margin
- 5.63%
- Net Margin
- 6.24%
- ROE
- 4.82%
- ROIC
- 2.39%
Growth & Income
- Revenue
- $12.70B · 34.85%
- Net Income
- $792.57M · 937.54%
- EPS
- $0.47 · 908.95%
- Op Income
- $1.97B
- FCF YoY
- 2327.06%
Performance & Tape
- 52W High
- $15.12
- 52W Low
- $7.08
- 50D MA
- $10.78
- 200D MA
- $11.27
- Beta
- 0.24
- Avg Volume
- 3.46K
Get TickerSpark's AI analysis on IVBXF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our IVBXF Coverage
We haven't published any research on IVBXF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IVBXF Report →